Machine learning model for predicting outcomes of biologic therapy in psoriasis - 01/06/23
, Zarqa Ali, MD b, Kawa K. Ajgeiy, MD c, Maiken G. Dalager, MD d, Tomas N. Dam, MD e, Alexander Egeberg, MD b, Christoffer V.S. Nissen, MD b, Lone Skov, MD f, Simon Francis Thomsen, MD b, Sepideh Emam, PhD g, ∗, Robert Gniadecki, MD a, ∗Key words : artificial intelligence, biologics, drug survival, machine learning, psoriasis, therapy
| Funding sources: This study was funded by a start-up grant from the Department of Medicine, University of Alberta to RG. AXD was supported by summer studentships from Alberta Innovates and the Canadian Association of Psoriasis Patients. |
|
| IRB approval status: Not applicable. |
|
| Previous Publication: Data from this study has been uploaded as pre-print to medRxiv. |
|
| Reprints not available from the authors. |
Vol 88 - N° 6
P. 1364-1367 - juin 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
